{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.36","upperLimit":"22.93","value":"17.48"},{"groupId":"OG001","lowerLimit":"2.10","upperLimit":"10.55","value":"6.70"},{"groupId":"OG002","lowerLimit":"1.97","upperLimit":"4.60","value":"3.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Overall survival was defined as the length of time from the first dose of study drug (Day 1) until the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with fibroblast growth factor (FGF) receptor 2 (FGFR2) rearrangements or fusions self-administered oral pemigatinib at a starting dose of 13.5 milligrams (mg) once daily (QD) on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG000","title":"Cohort A: FGFR2 Rearrangements or Fusions"},{"description":"Participants with all other FGF/FGFR alterations self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions"},{"description":"Participants with no FGF/FGFR alterations self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles (United States only). Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG002","title":"Cohort C: Negative for FGF/FGFR Alterations"},{"description":"Participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.","id":"OG003","title":"Other"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population. Two participants were assigned to a group labeled \"Other\" and were excluded from the EEP because the local laboratory FGF/FGFR results could not be confirmed centrally. The 95% confidence intervals were calculated using the Brookmeyer and Crowley's method.","reportingStatus":"POSTED","timeFrame":"up to 51.32 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}